In this article:

uniQure (QURE) Received its Third Buy in a Row

In this article:
In this article:

After H.C. Wainwright and Raymond James gave uniQure (NASDAQ: QURE) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Uy Ear maintained a Buy rating on uniQure yesterday and set a price target of $52.00. The company’s shares closed last Thursday at $19.39, close to its 52-week low of $18.70.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.4% and a 16.7% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Avrobio.

uniQure has an analyst consensus of Strong Buy, with a price target consensus of $58.29.

See the top stocks recommended by analysts >>

uniQure’s market cap is currently $913.2M and has a P/E ratio of 2.84.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Read More on QURE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed